B
Bull
Bull · 25%ONCO
$4.05
Scenario price
$0.590
+0.144 (+24.34%)At close
Loading chart…
- High
- 0.678
- Open
- 0.508
- VWAP
- 0.58
- Volume
- 45.16M
- Mkt Cap
- —
- Low
- 0.481
- Amount
- 26.33M
- EV/EBITDA, TTM
- 0.00
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
AI analysis of Onconetix Inc (ONCO)
SellOnconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.
Valuation Metrics
The current forward P/E ratio for Onconetix Inc (ONCO) is 0.00, compared to its 5-year average forward P/E of -2.37.
Alphio AI Price Scenarios for ONCO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.510-26NewsfilterOnconetix Approves 1-for-10 Reverse Stock Split
8.509-15NASDAQ.COMOnconetix Provides Strategic Financing to Realbotix Ahead of Acquisition
8.509-03NASDAQ.COMOnconetix Acquires Realbotix, Launches Robot Pilot Program
9.508-27Yahoo FinanceOncopeptides Reports Strong Q2 2026 Earnings Growth
8.508-06GlobenewswireOnconetix Advances Acquisition of Realbotix Amid Humanoid Robotics Adoption
ONCO FAQ — answered by Alphio AI
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Onconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.